PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34687791-8 2022 Depletion of ATF3 or its upstream transcription factor, ATF4, attenuated IL-6Ralpha induction and IL-6 mediated sorafenib resistance. Sorafenib 112-121 activating transcription factor 4 Homo sapiens 56-60 34664408-0 2021 YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. Sorafenib 37-46 activating transcription factor 4 Homo sapiens 12-16 34072570-9 2021 In vitro experimental evidence suggested that sorafenib induced protein kinase RNA-like ER kinase (PERK)/activating transcription factor 4 (ATF4)-dependent ZFAS1 expression, and sorafenib resistance could be overcome by PERK/ATF inhibitors. Sorafenib 46-55 activating transcription factor 4 Homo sapiens 140-144 34072570-0 2021 PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells. Sorafenib 58-67 activating transcription factor 4 Homo sapiens 5-9 34072570-9 2021 In vitro experimental evidence suggested that sorafenib induced protein kinase RNA-like ER kinase (PERK)/activating transcription factor 4 (ATF4)-dependent ZFAS1 expression, and sorafenib resistance could be overcome by PERK/ATF inhibitors. Sorafenib 46-55 activating transcription factor 4 Homo sapiens 105-138 34072570-10 2021 Therefore, PERK/ATF4/ZFAS1 signaling axis might be an attractive therapeutic and prognostic biomarker for sorafenib therapy in HCC. Sorafenib 106-115 activating transcription factor 4 Homo sapiens 16-20 29062139-5 2017 Here we identified the RNA-binding protein named DDX3 as a promotor of ATF4 expression in cancer cells treated with sorafenib, an ER stress inducer used as a chemotherapeutic. Sorafenib 116-125 activating transcription factor 4 Homo sapiens 71-75 29544563-0 2018 Sorafenib induces renal cell carcinoma apoptosis via upregulating activating transcription factor 4. Sorafenib 0-9 activating transcription factor 4 Homo sapiens 66-99 29544563-2 2018 However, whether sorafenib improves renal cell carcinoma (RCC) through activating transcription factor 4 (ATF4) has never been explored. Sorafenib 17-26 activating transcription factor 4 Homo sapiens 71-104 29544563-2 2018 However, whether sorafenib improves renal cell carcinoma (RCC) through activating transcription factor 4 (ATF4) has never been explored. Sorafenib 17-26 activating transcription factor 4 Homo sapiens 106-110 29544563-4 2018 Furthermore, sorafenib is demonstrated to enhance the mRNA and protein levels of ATF4. Sorafenib 13-22 activating transcription factor 4 Homo sapiens 81-85 29544563-7 2018 More importantly, silencing of ATF4 could largely abolish sorafenib-induced upregulation of CHOP and PUMA in ACHN cells. Sorafenib 58-67 activating transcription factor 4 Homo sapiens 31-35 29544563-8 2018 Meanwhile, sorafenib-induced cell apoptosis may be dependent on the activation of ATF4 since knockdown of ATF4 partially reversed sorafenib-induced ACHN cell apoptosis. Sorafenib 11-20 activating transcription factor 4 Homo sapiens 82-86 29544563-8 2018 Meanwhile, sorafenib-induced cell apoptosis may be dependent on the activation of ATF4 since knockdown of ATF4 partially reversed sorafenib-induced ACHN cell apoptosis. Sorafenib 11-20 activating transcription factor 4 Homo sapiens 106-110 29544563-8 2018 Meanwhile, sorafenib-induced cell apoptosis may be dependent on the activation of ATF4 since knockdown of ATF4 partially reversed sorafenib-induced ACHN cell apoptosis. Sorafenib 130-139 activating transcription factor 4 Homo sapiens 82-86 29544563-8 2018 Meanwhile, sorafenib-induced cell apoptosis may be dependent on the activation of ATF4 since knockdown of ATF4 partially reversed sorafenib-induced ACHN cell apoptosis. Sorafenib 130-139 activating transcription factor 4 Homo sapiens 106-110 29544563-9 2018 In summary, the present study demonstrates that sorafenib activates ATF4-CHOP-PUMA pathway in RCC cells, resulting in enhanced ER stress-related cell apoptosis. Sorafenib 48-57 activating transcription factor 4 Homo sapiens 68-72 29431743-5 2018 Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking negative regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription. Sorafenib 17-26 activating transcription factor 4 Homo sapiens 74-78 29431743-6 2018 Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 production in vitro. Sorafenib 74-83 activating transcription factor 4 Homo sapiens 24-28 29431743-9 2018 Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7-IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans. Sorafenib 56-65 activating transcription factor 4 Homo sapiens 90-94 31523192-0 2019 Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway. Sorafenib 67-76 activating transcription factor 4 Homo sapiens 94-98 31523192-5 2019 ER stress inhibitors significantly blocked sorafenib-induced autophagy, selective knockdown of PERK and activating transcription factor 4 (ATF4) expression reduced sorafenib-induced autophagy activity compared with knockdown of the other two UPR pathways, and silencing ATF4 inhibited the expression of Beclin1. Sorafenib 43-52 activating transcription factor 4 Homo sapiens 139-143 31523192-5 2019 ER stress inhibitors significantly blocked sorafenib-induced autophagy, selective knockdown of PERK and activating transcription factor 4 (ATF4) expression reduced sorafenib-induced autophagy activity compared with knockdown of the other two UPR pathways, and silencing ATF4 inhibited the expression of Beclin1. Sorafenib 164-173 activating transcription factor 4 Homo sapiens 104-137 31523192-5 2019 ER stress inhibitors significantly blocked sorafenib-induced autophagy, selective knockdown of PERK and activating transcription factor 4 (ATF4) expression reduced sorafenib-induced autophagy activity compared with knockdown of the other two UPR pathways, and silencing ATF4 inhibited the expression of Beclin1. Sorafenib 164-173 activating transcription factor 4 Homo sapiens 139-143 31523192-5 2019 ER stress inhibitors significantly blocked sorafenib-induced autophagy, selective knockdown of PERK and activating transcription factor 4 (ATF4) expression reduced sorafenib-induced autophagy activity compared with knockdown of the other two UPR pathways, and silencing ATF4 inhibited the expression of Beclin1. Sorafenib 164-173 activating transcription factor 4 Homo sapiens 270-274 31523192-7 2019 Interestingly, a low concentration of melatonin increased the sensitivity of HCC to sorafenib by inhibiting autophagy through the PERK-ATF4-Beclin1 pathway. Sorafenib 84-93 activating transcription factor 4 Homo sapiens 135-139 28553953-7 2017 We further found evidence that ATF4-induced proliferation can be attenuated by pharmacological or genetic xCT inhibition and ferroptosis inducers such as sorafenib, erastin and GPx4 inhibitor RSL3. Sorafenib 154-163 activating transcription factor 4 Homo sapiens 31-35 28553953-10 2017 Conversely, ATF4 knockdown renders cells susceptible for erastin, sorafenib and RSL3-induced ferroptosis. Sorafenib 66-75 activating transcription factor 4 Homo sapiens 12-16 21601561-4 2011 Sorafenib induced ATF4-mediated Redd1 expression, leading to mTOR inhibition-the upstream signal for down-regulation of survivin. Sorafenib 0-9 activating transcription factor 4 Homo sapiens 18-22 21601561-7 2011 We further found that Redd1-induced mTOR down-regulation and ATF4/CHOP-induced expression of the TRAIL receptor DR5 associated with sorafenib treatment helped sensitize cells to TRAIL-induced apoptosis. Sorafenib 132-141 activating transcription factor 4 Homo sapiens 61-65